|
Summary of antimalarial clinical trials conducted in Uganda 2002 – 2007 |
||||||
| Trial |
Kampala 1 |
UMSP 1 |
UMSP 2 |
UMSP 3 |
UMSP 4 |
Kampala 2 |
|
|
||||||
| Study site(s) |
Kampala |
Kyenjojo, Mubende, Kanungu |
Jinja, Arua, Tororo, Apac |
Tororo |
Apac |
Kampala |
|
|
||||||
| Years conducted |
August 2002 – July 2003 |
December 2002 – June 2003 |
November 2002 – May 2004 |
December 2004 – July 2005 |
May – July 2006 |
November 2004 – May 2007 |
|
|
||||||
| Regimens evaluated* |
CQ+SP |
CQ+SP |
CQ+SP |
AS+AQ |
AL |
AQ+SP |
| AQ+SP |
AQ+SP |
AQ+SP |
AL |
DP |
AS+AQ |
|
| AS+AQ |
AS+AQ |
AL |
||||
|
|
||||||
| Duration of follow-up |
28 days |
28 days |
28 days |
42 days |
42 days |
42 days |
| Age range of participants |
0.5 – 10 years |
≥ 6 months |
≥ 6 months |
1 – 10 years |
0.5 – 10 years |
1 – 10 years |
| Total study treatments |
400 |
1105 |
2160 |
408 |
421 |
1120 † |
| Efficacy outcome assigned |
384 (96%) |
1057 (96%) |
2081 (96%) |
403 (99%) |
417 (99%) |
1108 (99%) |
|
|
||||||
| Total SAEs |
16 |
41 |
20 |
2 |
6 |
18 |
| Convulsions |
4 |
15 |
4 |
1 |
3 |
9 |
| Altered mental status |
1 |
0 |
2 |
0 |
0 |
0 |
| Anemia |
5 |
6 |
3 |
0 |
0 |
0 |
| Vomiting |
2 |
13 |
1 |
0 |
0 |
1 |
| Weakness |
0 |
3 |
1 |
0 |
0 |
2 |
| Respiratory illness |
1 |
1 |
4 |
1 |
0 |
2 |
| Other |
3 |
3 |
5 |
0 |
3 |
4 |
|
* CQ+SP: chloroquine + sulphadoxine-pyrimethamine; AQ+SP: amodiaquine + sulphadoxine-pyrimethamine; AS+AQ: artesunate + amodiaquine; AL: artemether-lumefantrine; DP: dihydroartemisinin-piperaquine † Of 602 children enrolled into the Kampala 2 cohort study, 382 were diagnosed with at least one episode of uncomplicated malaria and were treated with a total of 1120 study treatments. | ||||||
Staedke et al. Malaria Journal 2008 7:107 doi:10.1186/1475-2875-7-107 |
||||||